Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center

Nathaniel A Cohen; David Choi; Tenzin Choden; Noa Krugliak Cleveland; Russell D Cohen; David T Rubin

doi:10.1016/j.cgh.2022.03.035

Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center

Clin Gastroenterol Hepatol. 2023 Aug;21(9):2407-2409.e2. doi: 10.1016/j.cgh.2022.03.035. Epub 2022 Apr 2.

Authors

Nathaniel A Cohen¹, David Choi¹, Tenzin Choden¹, Noa Krugliak Cleveland¹, Russell D Cohen¹, David T Rubin²

Affiliations

¹ University of Chicago Inflammatory Bowel Disease Center, Chicago, Illinois.
² University of Chicago Inflammatory Bowel Disease Center, Chicago, Illinois. Electronic address: [email protected].

Abstract

Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colon and rectum. Long-term therapy is generally required to achieve and maintain disease control.¹ In May 2021 the US Food and Drug Administration approved the use of ozanimod in patients with moderate to severe UC. We describe the first report of the use of ozanimod in real-world clinical practice.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Colitis, Ulcerative* / drug therapy
Humans
Indans / therapeutic use
Oxadiazoles / therapeutic use
United States

Substances

ozanimod
Indans
Oxadiazoles

Grants and funding

T32 DK007074/DK/NIDDK NIH HHS/United States